• ImmunityBio is collaborating with Accord Healthcare and Uniphar to expand European access to bladder cancer therapy ANKTIVA.
• Accord provides commercial expertise and market access support; Uniphar handles supply chain and distribution services.
• The first European patients received ANKTIVA with BCG in Germany and Austria for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
• European Commission conditional marketing authorization in February 2026 covers all 27 EU member states plus Iceland, Norway and Liechtenstein.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104114389) on November 04, 2026, and is solely responsible for the information contained therein.